This Plain Language Summary of Publication article (PLSP) from Future Oncology examined acute lymphoblastic leukemia patients who received inotuzumab ozogamicin before stem cell transplant. Researchers analyzed post-transplant survival rates, deaths from various causes, and side effects, including the potentially life-threatening veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS).

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Five-Year Real-World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B-Cell Precursor Acute Lymphoblastic Leukemia’ and was published in the American Journal of Haematology.

Visit Wiley using the link to read the original article.